Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds.

MLA

Törn, C., et al. “Glutamic Acid Decarboxylase Antibodies (GADA) Is the Most Important Factor for Prediction of Insulin Therapy within 3 Years in Young Adult Diabetic Patients Not Classified as Type 1 Diabetes on Clinical Grounds.” Diabetes/Metabolism Research and Reviews, vol. 16, no. 6, Nov. 2000, pp. 442–47. EBSCOhost, https://doi.org/10.1002/1520-7560(2000)9999:9999<::aid-dmrr152>3.0.co;2-t.

APA

Törn, C., Landin-Olsson, M., Ostman, J., Scherstén, B., Arnqvist, H., Blohmé, G., Björk, E., Bolinder, J., Eriksson, J., Littorin, B., Nyström, L., Sundkvist, G., & Lernmark, A. (2000). Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as Type 1 diabetes on clinical grounds. Diabetes/Metabolism Research and Reviews, 16(6), 442–447. https://doi.org/10.1002/1520-7560(2000)9999:9999<::aid-dmrr152>3.0.co;2-t

Chicago

Törn, C, M Landin-Olsson, J Ostman, B Scherstén, H Arnqvist, G Blohmé, E Björk, et al. 2000. “Glutamic Acid Decarboxylase Antibodies (GADA) Is the Most Important Factor for Prediction of Insulin Therapy within 3 Years in Young Adult Diabetic Patients Not Classified as Type 1 Diabetes on Clinical Grounds.” Diabetes/Metabolism Research and Reviews 16 (6): 442–47. doi:10.1002/1520-7560(2000)9999:9999<::aid-dmrr152>3.0.co;2-t.